By Doug Macron

Gradalis has joined the ranks of clinical-stage RNAi drug developers after recently initiating a phase I study of a cancer therapy that combines its bi-functional shRNA technology with an immune system stimulator, RNAi News has learned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

In Science this week: environmental DNA can help in studies of marine animals, and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.